PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported third quarter 2025 results and announced a major expansion of its pipeline with a new induced pluripotent stem cell (iPSC)-derived beta islet program for Type 1 diabetes (T1D), marking one of the company’s most ambitious therapeutic efforts to date. The program, CNTY-813, is expected to enter Investigational New Drug (IND)-enabling studies by year-end 2025, with an IND submission planned as early as 2026.
CEO Brent Pfeiffenberger said the preclinical data package points to “a tremendous opportunity to potentially deliver a functional cure for T1D,” citing robust glucose-normalization data, evidence of durable insulin production, and immune-evasive engineering powered by the company’s Allo-Evasion™ 5.0 technology.
The company also emphasized that CNTY-308, its CD19-targeted CAR-iT program for B-cell–mediated diseases, remains on track for a planned clinical trial initiation in 2026.
Pipeline Highlights
Century’s new T1D program, CNTY-813, leverages the company’s iPSC differentiation capabilities and its immune-evasive cell engineering platform. Preclinical datasets show rapid and sustained glycemic control without the need for chronic immunosuppression—an outcome the company says could “reshape the long-term care model for T1D,” pending regulatory clearance.
Meanwhile, CNTY-308 continues progressing through IND-enabling studies. The engineered CD4+/CD8+ ab CAR-iT therapy is designed for functional parity with primary T cells and is positioned as a potential treatment for a broad range of B-cell–driven disorders.
Century also confirmed continuing development of CNTY-101 through the investigator-sponsored CARAMEL Phase 1/2 trial led by researchers at Friedrich-Alexander University Erlangen-Nürnberg. Initial clinical data from CNTY-101 are expected December 5, 2025. As part of a reprioritization effort, the company will discontinue its own CALiPSO-1 trial after favorable but preliminary safety data across five treated patients.
Financial Results
Century closed the quarter with $132.7 million in cash, cash equivalents, and marketable securities, down from $220.1 million at the end of 2024 but sufficient to fund operations into the fourth quarter of 2027.
R&D expenses declined to $22.5 million from $27.2 million a year earlier, reflecting reduced personnel and manufacturing costs alongside higher lab spending tied to advancing preclinical and clinical programs. G&A expenses dropped to $6.8 million from $8.4 million, driven largely by a $1.4 million gain from a lease modification.
The company reported a third-quarter net loss of $34.4 million, compared with a loss of $31.2 million in the same period last year.
With two major programs moving toward clinical readiness and a strengthened financial outlook, Century said it will continue focusing resources on therapies with the potential to deliver “high-impact, potentially curative outcomes” for patients across autoimmune and metabolic diseases.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.